MLR Maelor

RNS Number:1969L
Maelor PLC
19 April 2005

   Maelor Appoints American Australian Medical, Inc., as Exclusive ContiSolTM
            Distributor for the Unites States of America and Canada


19th April 2005:  Maelor plc, the specialist healthcare products company, today
announces that it has signed an exclusive distribution agreement with American
Australian Medical, Incorporated (AAM), for the sale and marketing of ContiSol,
Maelor's range of urethral catheter cleansing solutions, in the United States
and Canada.


AAM is a marketer and distributor of specialist urological and pain management
products throughout North America. Currently the company has 21 dedicated
representatives and an experienced marketing team supporting the sales force.


ContiSol is a range of cleansing solutions designed to prolong the life of
indwelling urethral catheters and to prevent blockages.  By incorporating a
bellows design it gently flushes the catheter, thus reducing the need for
expensive and uncomfortable replacement.  The nurse or patient administering
ContiSol is able to control accurately both the rate and volume of delivery
whilst maintaining the highest possible aseptic standards.  ContiSol is
currently available in Spain, Greece and Cyprus, and is distributed in the UK
and Ireland by Bard Limited under their brand name OptiFlo(R).  The product
currently has a 45% share of the UK market, which is estimated to be worth in
excess of #5 million (source: IMS, February 2005).


Stephen Appelbee, CEO of Maelor, said:


"ContiSol is already approved for use in Canada, and the current clinical trial
being co-ordinated by the University of Alberta will act as a springboard for
the early adoption of the product.  AAM is committed to developing innovative
products, and highlighting their benefits to healthcare professionals.  We have
deliberately partnered ContiSol with a specialist company which can give us
immediate access both to the Canadian market and to local regulatory expertise
in the world's biggest medical products market, the United States."


Paxton Wong, President of AAM, said:


"American Australian Medical is pleased to be working with Maelor.  We believe
that ContiSol represents the state of the art in the urethral catheter
maintenance market.   We look forward to an excellent contribution from this
high quality product, and helping Maelor to expedite a marketing approval for
ContiSol in the United States."



For further information:


Maelor plc
Stephen Appelbee, Chief Executive Officer                01978 810153


Financial Dynamics
Ben Atwell/Lucy Briggs                                   0207 831 3113



Notes to Editors:


Maelor plc


Maelor is an AIM-listed specialist healthcare products company, which operates
on a virtual basis, outsourcing both product development and manufacturing. The
company has several products on the market including OptiFlo, ContiSol and
Volplex(R).


Maelor has various products under development including micelle propofol, a
reformulation of the world's biggest selling general anaesthetic.


American Australian Medical, Incorporated


Founded in 1989, American Australian Medical offers a range of innovative
products in the urological and pain management areas of patient care.  AAM is
the North American distributor of the O'Neil Sterile Field Urinary Catheter,
manufactured by GO Medical in Australia.  The O'Neil Catheter greatly reduces
the incidence of urinary tract infections.



ContiSolTM and Volplex(R) are trade marks of Maelor Pharmaceuticals Limited
OptiFlo(R) is a trade mark of Bard Limited




                      This information is provided by RNS
            The company news service from the London Stock Exchange
END

AGRBUGDSXXBGGUI

Maelor (LSE:MLR)
Historical Stock Chart
From Nov 2024 to Dec 2024

Maelor (LSE:MLR)
Historical Stock Chart
From Dec 2023 to Dec 2024